C-EARLY results support Cimzia's use sooner for severe RA
This article was originally published in Scrip
Executive Summary
Data presented at the European League Against Rheumatism (EULAR) annual congress in Rome support the early use of UCB's anti-TNF drug Cimzia (certolizumab pegol) in certain rheumatoid arthritis patients who have not yet been treated with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).